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Biologics are among the most commonly prescribed medications for several chronic inflammatory diseases. Tumor 
necrosis factor alpha inhibitors, more so than other agents, have been observed to cause drug-induced liver injury. 
Additionally, because the approval and popularity of checkpoint inhibitors have grown, similar patterns of liver injury 
have been documented, with a majority of cases describing immune-mediated hepatitis. Although the exact mecha-
nism of injury is unknown, various host and medication characteristics play a role in the outcome of the molecular 
cascade invoked by biologics. Prognosis is usually favorable with cessation of the offending agent, but cases of acute 
liver failure requiring liver transplantation have also been observed. Therefore, algorithms have been created to assist 
clinicians in treating drug-induced autoimmune hepatitis, mostly with corticosteroids. Additionally, case reports have 
documented successfully rechallenging patients with a different biologic without recurrence of liver injury, but data are 
limited. Further investigation is warranted regarding the potential for cross-reactivity and mechanism of injury to de-
velop guidelines to aid clinicians in further management of these patients. (Hepatology Communications 2020;4:172-184).
A 63-year-old African American man with ulcerative colitis (UC) presented to the clinic with persistently elevated liver enzymes after 
receiving three doses of infliximab 5 mg/kg (470 mg/
dose) due to multiple UC flare-ups. His presenting 
bilirubin was 16  mg/dL (normal <1.2  mg/dL), alka-
line phosphatase (ALP) 464 U/L (<115 U/L), alanine 
aminotransferase [ALT] 1,164  U/L (<55  U/L), and 
aspartate aminotransferase (AST) 896 U/L (<34 U/L). 
At follow-up visits, his aminotransferases stabilized 
but his bilirubin continued to uptrend. Initial work up 
for etiology of the liver injury was negative, including 
a negative antinuclear antibody (ANA) and smooth 
muscle actin and normal immunoglobulin G (IgG). A 
liver biopsy showed cholestatic hepatitis with patchy 
lobular necrosis, ductopenia with marked duct injury, 
and mild steatosis without fibrosis.
He was admitted to the hospital 2 weeks later with 
a bilirubin of 55.3 mg/dL and a Model for End-Stage 
Liver Disease score of 38, consistent with subfulmi-
nant liver failure. He underwent a liver transplan-
tation 14  weeks after his first dosage of infliximab. 
The explanted liver pathology showed severe lobular 
cholestasis with patchy hepatocyte necrosis with severe 
bile duct injury as well as patchy bile duct loss (Fig. 1). 
No fibrosis was identified. The extrahepatic and large 
bile ducts were sampled and did not show evidence of 
primary sclerosing cholangitis. No florid duct lesions or 
granulomas that would suggest primary biliary cholangi-
tis were identified. A diagnosis of autoimmune hepatitis 
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(AIH) was unlikely given the lack of positive autoan-
tibodies, prominence of plasma cells, interface activity, 
and fibrosis along with the presence of marked cholesta-
sis and duct injury/loss with minimal inflammation on 
the explanted liver. Instead, these findings are consistent 
with the first published case of infliximab-induced van-
ishing bile duct syndrome and subsequent liver failure 
that required a liver transplantation.(1)
Tumor Necrosis Factor 
Alpha Inhibitors
Tumor necrosis factor alpha (TNF-α) is a pro-
tein produced by lymphocytes and macrophages that 
has both beneficial and harmful effects due to its 
inflammatory, proliferative, apoptotic, and antitu-
mor effects.(2) In the 1990s, TNF-α inhibitors were 
developed to combat the underlying biologic disease 
processes seen in rheumatoid arthritis (RA) and 
Crohn’s disease. Infliximab was the first agent to be 
approved by the U.S. Food and Drug Administration 
(FDA) in 1998 for the treatment of Crohn’s dis-
ease.(3,4) Initially, FDA labels for these TNF-α 
inhibitors only included cautions on injection site 
reactions, headache, nausea, rash, and arthralgias.(5) 
It was not until an FDA postmarketing surveillance 
program that documented over 130 reports of liver 
injury from either infliximab or etanercept treat-
ment within 5  years did the labels start to include 
hepatobiliary adverse effects.(6)
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Fig. 1. Pathology from the explanted liver, November 2018. (A) Extensive hepatocyte dropout and marked cholestasis with minimal 
lobular lymphocytic inflammation and no fibrosis. Hematoxylin and eosin stain, magnification ×200. (B) Cytokeratin 7 immunostain 
(magnification ×400) highlights the ductal epithelium of a severely degenerative interlobular bile duct in a portal area. There is minimal 
staining of periportal immature hepatocytes. No significant ductular reaction is present, which would also stain with the immunostain, 
indicating minimal reconstitution of the ducts.
Hepatology CommuniCations, February 2020SHAH, SUNDARAM, BJÖRNSSON
174
Although the underlying mechanism of biologic- 
induced liver injury remains unknown, TNF-α inhib-
itors lead to an abundance of lymphocytes by pre-
venting the normal suppression of B-cell production 
and apoptosis of cluster of differentiation (CD)8+ T 
cells.(7) Additionally, TNF-α acts on two receptors 
(TNF receptor 1 and 2) to manage opposing effects 
(Fig. 2). When TNF-α is inhibited, the balance 
between effector and regulatory T cells is altered and 
can result in either liver injury or regeneration. The 
tipping of the scale depends probably on genetics and 
the immunologic status of the host.(7) Additionally, it is 
still unclear why infliximab seems to more commonly 
elicit AIH compared to other TNF-α inhibitors. 
Some believe that this might be due to infliximab’s 
mouse–human chimeric antibody make-up compared 
to the full human make-up of the remaining biologics, 
although this remains speculative.(8-12)
Pharmacokinetics and pharmacodynamics also 
play a role in the clearance and half-life of biolog-
ics, which impact the possibility of adverse effects. 
Patients who are predisposed to faster clearance/
short half-life, such as those with severe underly-
ing inflammatory disease, low albumin, or high 
body weight, may need shorter dose intervals, which 
might put them at higher risk of drug-induced liver 
injury (DILI).(13)
In this review, we describe the hepatotoxicity asso-
ciated with biologics, with an emphasis on TNF-α 
inhibitors and checkpoint inhibitors. Our purpose 
is to help clinicians identify potential adverse effects 
of these biologics on the liver, identify strengths and 
weakness in current literature, and aid in diagnosis 
and management if such hepatotoxic events occur.
A bibliographical search was performed in 
PubMed using the following key words: biologic, 
TNF inhibitors, drug-related liver injury, drug- 
induced liver injury, liver injury, infliximab, etaner-
cept, adalimumab, golimumab, certolizumab, 
checkpoint inhibitors, case report, and case series. 
Reference lists from studies found were also searched 
for further relevant studies.
All study designs from 2001 to 2018 that sug-
gested a pattern of DILI injury regardless of method 
of evaluation were included, such as FDA reports, case 
reports, case series, and literature reviews. These find-
ings are summarized in Table 1.
patteRns oF liVeR inJuRy 
RelateD to tnF-α inHiBitoR 
use
The FDA released a report in 2003 regarding ele-
vated aminotransferases between 2 and 3 times the 
Fig. 2. Mechanism of anti-TNF-α-induced liver injury. Inhibition of the TNF-α pathway disrupts the balance between an inflammatory 
and anti-inflammatory response through receptors on T cells. Depending on host characteristics, this imbalance may either lead to liver 
injury or liver regeneration.
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upper limit of normal (ULN) during TNF-α inhib-
itor treatment, with a prevalence of 37%-42% com-
pared to 29%-36% in control groups.(14) Reviews 
since then have reported complications related to 
TNF-α inhibitors,(15) including instances of hepati-
tis or cholestasis,(16-26) acute liver failure (ALF),(27-31) 
fulminant hepatitis B reactivation,(30-32) induction 
of autoimmune/immune-mediated hepatitis,(33-44) 
and even the need for emergent liver transplanta-
tion.(45,46) Among 176 patients with inflammatory 
bowel disease (IBD) treated with infliximab, trans-
aminitis occurred in 36% of patients, of whom 73% 
of cases had spontaneous resolution even while con-
tinuing the medication.(26)
Of the nine cases of TNF-α inhibitor-induced ALF, 
8 of the described patients were taking infliximab 
while the other patient was on adalimumab.(27,45,47-50) 
The latency between initial drug exposure and ALF 
ranged from 3  days to 1 year. The pattern of liver 
injury was determined in seven cases, of which four 
were found to have hepatocellular injury, two with 
cholestatic injury, and one with mixed injury.(47) In 
three of these nine cases, ANA went from negative 
before TNF-α inhibitor initiation to positive during 
ALF.(27,45,47-50) Liver biopsy was performed in seven 
cases, which showed clear histologic autoimmune 
features. Six of the nine cases went on to emergent 
transplantation, with the other three recovering liver 
function with steroid therapy. Given the wide range 
of latency, this may suggest an idiosyncratic DILI 
rather than a dose-dependent toxicity, which has been 
described in other studies as well.(5,51,52)
Ghabril et al.(23) analyzed 34 cases of DILI related 
to TNF-α inhibitors and found the most common 
presentation to be an autoimmune phenotype with 
improvement after drug withdrawal.(23) In large ret-
rospective studies, mild DILI (defined as ALT >2× 
ULN and/or ALP>2× ULN) was reported to have 
a 0.2%-11% incidence, with the majority implicat-
ing infliximab.(51,53,54) The absolute risk of DILI for 
patients that were started on infliximab was found in 
1 of 120 users, 1 of 270 for adalimumab, and 1 of 430 
for etancercept.(53) The median duration of TNF-α 
inhibitors therapy was 3.3 months for those who 
taBle 1. types oF BiologiCs anD potential aDVeRse eFFeCts on tHe liVeR
Name Mechanism of Action Potential Hepatotoxic Effects
Infliximab TNF-α inhibitor (monoclonal mouse–human chimeric antibody) Hepatocellular and cholestatic patterns of injury, reactivation of 
hepatitis B, AIH, ALF, vanishing bile duct syndrome
Etanercept TNF-α inhibitor (human form of TNF-α receptor fused with IgG) Hepatocellular and cholestatic patterns of injury, reactivation of 
hepatitis B, AIH
Adalimumab TNF-α inhibitor (monoclonal antibody) Hepatocellular and cholestatic patterns of injury, reactivation of 
hepatitis B, AIH
Certolizumab TNF-α inhibitor (Fab fragment of a monoclonal antibody) Reactivation of hepatitis B
Golimumab TNF-α inhibitor (human monoclonal immunoglobulin antibody) Hepatocellular pattern of injury, reactivation of hepatitis B
Rituximab CD20 surface antigen antagonist (chimeric mouse/human monoclo-
nal antibody)
Hepatocellular and cholestatic patterns of injury, reactivation of 
hepatitis B, AIH, ALF
Tocilizumab IL-6 receptor antagonist (human monoclonal antibody) Hepatocellular pattern of injury
Anakinra IL-1 receptor antagonist (recombinant) Hepatocellular and biliary pattern of injury, ALF
Abatacept CTLA-4 antagonist (human fusion protein of the cell-surface marker 
CTLA-4 and immunoglobulin)
Hepatocellular pattern of injury, reactivation of hepatitis B, AIH
Ipilimumab CTLA-4 blockade checkpoint inhibitor (human monoclonal antibody) Hepatocellular pattern of injury, immune-mediated hepatic injury, 
fibrin ring granulomas
Nivolumab PD-1 blockade checkpoint inhibitor (human monoclonal antibody) Hepatocellular and biliary pattern of injury, immune-mediated 
hepatic injury
Pembrolizumab PD-1 blockade checkpoint inhibitor (humanized monoclonal 
antibody)
Hepatocellular and biliary pattern of injury, immune-mediated 
hepatic injury, vanishing bile duct syndrome
Cemiplimab PD-1 blockade checkpoint inhibitor (monoclonal antibody) Hepatocellular pattern of injury, immune-mediated hepatic injury
Atezolizumab PD-L1 blockade checkpoint inhibitor (humanized monoclonal 
antibody)
Hepatocellular pattern of injury, immune-mediated hepatic injury
Avelumab PD-L1 blockade checkpoint inhibitor (humanized monoclonal 
antibody)
Hepatocellular pattern of injury, immune-mediated hepatic injury
Durvalumab PD-L1 blockade checkpoint inhibitor (humanized monoclonal 
antibody)
Hepatocellular pattern of injury, immune-mediated hepatic injury
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developed DILI, mostly after four infusions of inflix-
imab, and this time line was corroborated in a review 
of 26 cases of infliximab-induced hepatocellular injury 
by Ghabril et al.(23,54)
The most common form of liver injury related to 
TNF-α inhibitors has been shown to be hepatocellular 
injury with autoantibodies, mostly with positive ANA 
and some with anti-smooth muscle antibody, and his-
tologic features consistent with AIH. Development 
of this pattern of injury has been reported in up to 
92% of TNF-α inhibitor-induced DILI.(5,23,51,54-56) 
Additionally, there seems to be a lack of cross-reactivity 
between TNF-α inhibitors, possibly due to the dif-
ference in molecular structure of these agents. For 
instance, a patient with infliximab-induced hepatocel-
lular injury that resolved after cessation of infliximab 
was then successfully transitioned to adalimumab 
without DILI,(52) which has also been reported in 
other studies.(23,52,54,57-59) Additionally, even though 
ANA can be used to diagnose AIH, positive ANA 
status before the initiation of therapy did not seem 
to place the patient at greater risk of developing 
DILI.(54) Out of the patients that developed an AIH-
like picture from TNF-α inhibitors, at least half of the 
patients required steroids while the other half recov-
ered after stopping treatment.(23,53,54)
There have also been several case series that 
demonstrated more severe DILI, defined as a more 
prolonged cholestasis or acute liver injury.(60) One 
study from Taiwan investigated serious hepatic events, 
defined as an event requiring hospitalization, and 
reported 0.75 events per 100 person-years on adali-
mumab and 0.39 events per 100 person-years on 
etanercept.(61) Another study described eight cases of 
TNF-α inhibitor-induced hepatitis that was defined 
as ALT >10× ULN out of a cohort of 600 patients, 
with 7 of them related to infliximab.(55)
Steatosis and steatohepatitis have also been 
reported in patients taking TNF-α blockers, which 
can improve once treatment has been stopped.(62,63) 
Another study of 48 patients with psoriatic arthri-
tis with hepatic steatosis before initiation of TNF-α 
inhibitor therapy found worsening hepatic steatosis 
in those with persistent symptoms.(64) Although the 
mechanisms of TNF-α inhibitor-induced nonalco-
holic fatty liver disease is unclear, more patatin-like 
phospholipase domain containing 3 (PNPLA3) poly-
morphism I148M, a DNA sequence associated with 
increased hepatic fat level and inflammation, was 
found in patients who developed liver test abnormali-
ties compared to those who did not.(62)
speCiFiC tnF-α inHiBitoRs
infliximab
Infliximab, a monoclonal mouse–human chimeric 
antibody to TNF-α is currently used for IBD and 
RA. Although the overall risk of DILI with TNF-α 
inhibitors is low, there have been a disproportionate 
amount of liver injury reports related to infliximab 
compared to other drugs of the same class.(47) When 
AST and ALT elevations develop, this usually occurs 
after two to five infusions and can be transient and 
asymptomatic but do not always improve after ces-
sation of infliximab.(61) A hepatocellular pattern of 
injury is often seen along with induction of antibod-
ies, including ANA, smooth muscle antibody, and 
anti-double-stranded DNA. Lupus-like symptoms or 
AIH usually accompany these antibodies. Liver biopsy 
often shows interface hepatitis, focal liver cell necro-
sis, and intense mononuclear cell infiltrates that can 
include plasma cells.
Multiple studies have shown that 64%-80% 
of patients with infliximab-induced AIH did not 
improve with cessation of the drug alone and required 
steroids.(61,65) Patients have usually recovered after 
treatment, and relapse was not observed after com-
pleting a course of steroids.(65) There have also been 
documented cases of cholestatic forms of liver injury 
ranging from within a few days to 24 weeks after ini-
tiating therapy with infliximab.(16)
etanercept
Liver injury related to etanercept is less well doc-
umented compared to infliximab. It is a human form 
of TNF-α receptor fused with IgG used to treat 
rheumatologic conditions. Transient low elevations of 
ALT have been documented along with cholestatic 
and hepatocellular patterns of injury.(12) Similarly to 
infliximab, induction of AIH and ANA autoantibod-
ies has been noted. Latency has been reported to be as 
short as 2 weeks to as long as several years from initial 
dose of etanercept.(12)
Two cases have described etanercept-induced 
AIH.(66,67) One patient had systemic-onset juve-
nile idiopathic arthritis, and the other had RA with 
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Sjogren’s syndrome. They were found to have ele-
vated AST/ALT, total bilirubin, and gamma-glutamyl 
transpeptidase (GGT) along with positive antibodies. 
Liver biopsies showed extensive portal and periportal 
interface lymphoplasmacytic infiltration and panlob-
ular hepatitis along with single-cell necrosis, rosette 
formation, and collections of syncytial multinucle-
ated hepatocytes. Both patients were diagnosed with 
drug-induced AIH and responded well to prednisone 
after discontinuing etanercept.(66,67)
adalimumab
Adalimumab is a monoclonal antibody used to treat 
RA and IBD. Although it seems that adalimumab is 
less frequently associated with liver injury than inflix-
imab, it has also been associated with transient and 
mild serum aminotransferase elevations, reactivation 
of hepatitis B virus (HBV), AIH, and even choles-
tatic liver injury.(12) Two cases have been reported 
of patients developing drug-induced AIH within 
2-3 months of initiation of therapy.(68,69) One patient 
was treated for psoriatic arthritis and Crohn’s disease, 
while the other was treated for RA. Both experienced 
elevated liver enzymes, positive ANA, and elevated 
IgG, with liver biopsies showing portal fibrosis, peri-
portal lymphocytic infiltrates, and interface hepatitis. 
Both patients had an AIH score of 7, consistent with 
a definite diagnosis of AIH.(68,69)
Adalimumab was also demonstrated to cause 
cholestatic liver injury in a patient with chronic hep-
atitis C virus and RA who was treated with adalim-
umab due to RA reactivation.(70) At the third month 
of treatment, the patient began having pruritus with 
liver function tests showing elevations in GGT, ALP, 
and AST. A liver biopsy showed portal dystrophy, 
portal inflammation with eosinophils, lobular hepati-
tis, and microabscesses.(70)
Certolizumab and golimumab
Certolizumab is a humanized recombinant Fab 
fragment of a monoclonal antibody to TNF-α; it is 
used to treat RA and IBD and has been associated 
with a low rate of transaminitis, similar to the rate 
found with placebo therapy.(12) Although it is specu-
lated that, similar to other TNF-α inhibitors, it may 
cause reactivation of HBV, no cases have been docu-
mented thus far. Golimumab is a human monoclonal 
immunoglobulin antibody to TNF-α and is similarly 
used to treat RA and IBD. In controlled trials, serum 
ALT elevations occurred in up to 8% of patients ver-
sus 1%-3% of subjects on placebo. These elevations 
were mostly asymptomatic and self-limited. Only 
rarely did patients have to stop therapy because of ele-
vations above 5 times the ULN.(12) There have been 
no published cases thus far of acute liver injury due to 
golimumab.
otHeR BiologiCs
CD20 surface antigen antagonists
Rituximab, a chimeric mouse/human monoclonal 
antibody to the CD20 surface antigen on pre-B and 
mature B lymphocytes, has been approved for treating 
RA along with lymphoma and leukemia. A major-
ity of documented adverse reactions have described a 
self-limited hepatocellular pattern of injury in 10%-
15% of patients but often resolve even with continu-
ing therapy.(71) One case also describes an episode of 
cholestatic liver injury after being treated with ritux-
imab.(72) Rituximab is known to cause reactivation of 
HBV and can rarely cause ALF.(73)
Notably, rituximab has also been used for treat-
ment of refractory AIH. In a pilot study from Canada, 
6 patients with refractory AIH (due to persistent dis-
ease or intolerable side effects from prednisone or aza-
thioprine) were treated with rituximab with success.(74) 
Transaminases and IgG levels decreased with liver 
biopsies after 1 year, showing improvement in inflam-
mation as well. These findings were corroborated with 
case reports as well as single-center studies.(74)
interleukin-6 Receptor antagonists
Tocilizumab is a humanized monoclonal antibody 
to the interleukin (IL)-6 receptor that has been used 
for RA. A hepatocellular pattern of liver injury has 
been documented in several case reports, with liver 
biopsies showing focal necrosis with steatosis and early 
fibrosis with other etiologies of injury excluded.(75,76) 
In one case, tocilizumab was continued given nor-
malization of liver enzymes and remained stable at 
6 months of follow-up. In another case, treatment was 
discontinued and N-acetylcysteine was given until 
normalization of enzymes. There has also been a case 
describing ALF requiring liver transplant in a patient 
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who was treated with tocilizumab for RA.(77) Along 
with an otherwise negative work up, the explanted 
liver showed liver necrosis with ongoing cell death 
and no signs of proliferating hepatocytes, which sug-
gests a possible medication-induced etiology of injury.
il-1 Receptor antagonists
Anakinra is a recombinant IL-1 receptor antagonist 
that can be used for treating RA and juvenile idiopathic 
arthritis but also has been used for treating adult- 
onset Still’s disease, given the benefit in reducing liver 
inflammation. Anakinra has been linked to acute liver 
injury that mimics acute viral hepatitis, with a hepato-
cellular pattern of serum enzyme elevations and jaun-
dice, as described in multiple case reports.(75,78,79) One 
of these case reports used the Roussel Uclaf Causality 
Assessment Method evaluation, a scale used to pre-
dict whether liver injury can be attributed to a certain 
medication, which suggested anakinra-induced liver 
injury.(80) Discontinuation of anakinra led to normaliza-
tion of liver enzymes; other possible etiologies of injury 
were excluded. Two patients with adult-onset Still’s dis-
ease developed ALF during treatment with anakinra but 
resolved following withdrawal of the medication.(80,81) 
Although Still’s disease itself can be associated with the 
development of hepatitis, the improvement in clinical 
symptoms and liver injury once the culprit medication 
was stopped suggested the etiology was due to anak-
inra. Lastly, three cases of hepatitis in patients treated 
for juvenile idiopathic arthritis were also thought to be 
due to anakinra.(82) However, given the young age of 
these patients, there were multiple confounding factors, 
and this pattern of injury may have been due to a typical 
childhood infection that presented differently given the 
altering of the immune response from anakinra.
Biologic Disease-modifying 
antirheumatic Drug
Abatacept is a selective, costimulation modulator, 
recombinant human fusion protein of the cell-surface 
marker cytotoxic T lymphocyte antigen 4 (CTLA-4) 
and modified Fc region of human IgG that interferes 
with T-cell activation and is used to treat RA. Abatacept 
selectively inhibits T-cell activation by binding to CD80 
and CD86. In prelicensure controlled trials, a hepatocel-
lular pattern of injury occurred in about 3% of patients 
but was asymptomatic and self-limited. There are risks 
for reactivation of chronic HBV as well, but one case 
report documents an instance of drug-induced AIH 
that responded well to corticosteroid therapy.(83)
Checkpoint inhibitors
This class of medications targets specific points in 
the cell cycle to increase immune reactivity that aid 
in treating certain malignancies. Some of these medi-
cations block CTLA-4, others block programmed cell 
death receptor 1 (PD-1), and others also block pro-
grammed cell death ligand 1 (PD-L1). Hepatotoxicity 
has been reported to occur from 2% to 10% of patients 
within 3-6 months of starting treatment, with a mixed 
pattern of injury.(84) The first subgroup of the check-
point inhibitors, which includes ipilimumab, blocks 
the CTLA-4 antigen on cytotoxic T lymphocytes. 
Asymptomatic hepatitis has been seen following treat-
ment, and if detected early, skipping a dose and waiting 
3 weeks or more until the next dose can be acceptable if 
liver tests improve.(85) Liver histology has often revealed 
focal or confluent necrosis with prominent lymphocytic 
infiltrates of activated T cells, which is consistent with 
an immune-mediated hepatic injury.(86) In a study of 11 
cases of suspected ipilimumab-associated hepatitis, the 
distribution was found to be panlobular and resembled 
AIH.(86) Another study assessed the liver injury associ-
ated with ipilimumab, and no positive autoantibodies or 
IgG elevations were observed; stopping the immuno-
therapy and starting corticosteroids normalized the liver 
enzymes.(87) Although there were some shared features 
with AIH on liver histology, there were also differences 
that led the authors to believe that this was a separate 
idiosyncratic pattern of injury. Fibrin ring granulomas 
have also been described and are considered pathogno-
monic for ipilimumab-induced hepatic injury.(84)
Other checkpoint inhibitors, including nivolumab, 
pembrolizumab, and cemiplimab, are PD-1 antago-
nists that aim to modulate T-cell immune reactiv-
ity. Five patients treated with nivolumab, similar to 
ipilimumab, had immune-mediated liver injury that, 
after further investigation, was considered to be dis-
tinct from AIH.(87) A sustained liver injury marked 
by grade 4 ALT elevation has been reported to be 
refractory to steroid therapy, but the hepatocellu-
lar pattern of injury resolved about 5 months after 
discontinuation of nivolumab.(88) Another patient 
with worsening liver enzymes after nivolumab treat-
ment for metastatic melanoma had a liver biopsy 
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showing focal ductopenia and periductal fibrosis 
consistent with a pattern of biliary injury, so treat-
ment was stopped.(89) A similar pattern was seen 
with pembrolizumab, and despite prednisolone for 
presumed autoimmune-like hepatitis, bilirubin and 
ALP continued to worsen, which led to a biopsy 
and the eventual diagnosis of acute-onset vanishing 
bile duct syndrome secondary to pembrolizumab.(89) 
Additionally, a patient with pulmonary metastatic 
liver cancer was treated with pembrolizumab and 
despite improvement of metastatic lesions, developed 
ALF due to immune-related hepatitis.(90) This article 
also describes a patient with progressive epithelioid 
mesothelioma who was treated with pembrolizumab 
but soon developed a cholestatic pattern of injury 
with ductal loss on biopsy that ceased after the med-
ication was stopped.(89)
The PD-L1 inhibitors, such as atezolizumab, ave-
lumab, and durvalumab, increase immune reactivity 
to tumor neoantigens by blocking PD-L1 to treat 
bladder, lung, and metastatic cancers. Similar to other 
checkpoint inhibitors, immune-mediated hepatitis 
along with hepatocellular patterns of injury have been 
documented.
Combination therapy of the PD-1 blocking anti-
body nivolumab and the anti-CTLA-4 drug ipilim-
umab has been reported to result in immune-related 
hepatitis, which may be managed with steroids.(91,92) 
In one study, 25%-30% all-grade hepatitis and 15% 
incidence of grade 3 toxicity were found within the 
first 6 to 12 weeks after initiation of dual therapy.(93) 
However, 40% of patients who discontinued com-
bination therapy for toxicities experienced recurrent 
or distinct toxicities with anti-PD-1 monother-
apy resumption.(91) These data suggest that even 
with dual immune therapy, either ipilimumab or 
nivolumab may be the primary culprit in driving 
specific toxicities due to a high rate of 21% of clin-
ically distinct adverse effects following anti-PD-1 
rechallenge.(91) Therefore, the concept of “immune 
priming” by combination therapy may predispose 
patients to other toxicities.(91,94)
Despite these documented cases of checkpoint 
inhibitor-induced DILI, evaluation of other causes of 
liver injury should be considered. One study involving 
491 patients treated with pembrolizumab noted 14% 
of patients with liver injury, a majority of which was 
attributed to hepatic metastases rather than DILI; 
those with liver injury had lower tumor response and 
higher mortality, likely due to more advanced cancer 
before treatment. Therefore, thorough assessment for 
other etiologies of liver injury should be completed to 
not only assist with diagnosis but also with manage-
ment regarding appropriate use of immunosuppressive 
therapy.(95)
Management of  
Biologic-Induced Liver 
Injury
A previous consensus among experts for the safe 
use of infliximab in IBD gave recommendations that 
liver tests should be obtained before initiating treat-
ment, after induction, and every 4  months while on 
maintenance treatment.(46) Additionally, the state-
ment suggests avoiding or discontinuing infliximab 
therapy in patients found to have a transaminitis >3 
times the ULN. However, despite following such rec-
ommendations, severe liver injury with ALF has been 
reported.(27) Therefore, a new algorithm has been 
proposed.
According to these recommendations, the patient 
should be evaluated for underlying previous liver 
disease with baseline liver tests along with hepatitis 
screening. Next is the initiation of the TNF-α inhib-
itor therapy followed by rechecking liver tests every 
2 weeks for 8 weeks. If they are normal, repeat every 
8  weeks for the duration of treatment. However, if 
these tests are abnormal, monitoring must be done 
based on which value is above normal limits. If there is 
an isolated increase of ALT <3 times the ULN with-
out jaundice, recheck the hepatic panel every 2 weeks 
until resolution. If ALT >3 times the ULN (regardless 
of any increase in bilirubin or presence of jaundice), it 
is important to rule out other causes of elevated values 
and proceed with ultrasound or biopsy based on the 
resulting differential.(26)
At this point, if liver tests continue to worsen, the 
drug should be discontinued. N-acetyl-cysteine has 
been shown to improve transplant-free survival for 
patients not only with acetaminophen-induced ALF 
but also with non-acetaminophen ALF; however, 
patients with liver injury due to biologics have not 
been included in these studies.(96-98) Corticosteroids 
have also been administered with better results in 
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patients with DILI or AIH from TNF-α inhibi-
tor therapy.(5,54,61) Data from a single-center ret-
rospective cohort study support these findings and 
also showed that corticosteroids were most effec-
tive for severe liver injury with peak total bilirubin 
>243 μmol/L.(99) Generally, steroids were given after 
about 1 week in patients with severe DILI with two 
different schedules.
One option is a corticosteroid titration schedule 
with a reduction of the daily dose over several weeks 
(methylprednisolone 60-120  mg/day or prednisone 
40-60  mg/day for 3-5  days and then prednisone 
20 mg/day tapered by 5-10 mg weekly thereafter).(99) 
The other option is a corticosteroid pulse therapy using 
methylprednisolone 60-120  mg/day for 3-5  days.(99) 
Steroids not only decreased the mortality rate but also 
shortened the time duration to recovery.(99) Because 
data show a correlation between higher total biliru-
bin and the severity of liver disease, early identifica-
tion of signs of liver failure are important to prevent 
delay in therapy, especially in those who are prone to 
developing ALF.(100) Usually, corticosteroid therapy is 
associated with rapid improvement and can be dis-
continued with resolution of clinical and laboratory 
signs of injury, which can occur within 3-6  months 
of treatment, followed by histologic resolution 
3-8 months later.(5,54,61,101)
Management of Checkpoint 
Inhibitor-Induced Liver 
Injury
The American Society of Clinical Oncology 
created a clinical practice guideline to assist clini-
cians managing immune-related adverse events.(84) 
Regarding checkpoint inhibitor-induced hepatitis, 
the society recommends monitoring AST, ALT, 
and bilirubin before each infusion and/or weekly if 
there are any mild liver function test elevations. For 
patients with grade 1 hepatotoxicity (AST or ALT 
>ULN to 3× ULN and/or total bilirubin >ULN 
to 1.5× ULN), clinicians should continue to offer 
checkpoint inhibitor therapy with close monitor-
ing with the aforementioned tests 1-2 times weekly 
while ruling out other etiology and offering sup-
portive symptom control.
If there is grade 2 toxicity (AST or ALT >3 to 
<5× ULN and/or total bilirubin >1.5 to <3× ULN), 
therapy should be held temporarily and resumed only 
if toxicity improves to grade 1 or less.(84) Additionally, 
0.5 to 1 mg/kg/day prednisone or equivalent should be 
started if the liver function tests remain elevated with 
clinical symptoms over the next 3 to 5 days. Frequency 
of laboratory monitoring should be increased to every 
3 days. Checkpoint inhibitor therapy may be resumed 
if symptoms and liver injury improve to grade 1 or 
less on ≤10 mg/day of corticosteroid, which should be 
tapered over at least 1 month.
Grade 3 hepatotoxicity (symptomatic dysfunction, 
fibrosis found on a liver biopsy, compensated cirrhosis, 
reactivation of chronic hepatitis, AST or ALT 5-20× 
ULN, and/or total bilirubin 3-10× ULN) should result 
in permanent discontinuation of checkpoint inhibitors 
along with immediately starting 1 to 2 mg/kg/day of 
methylprednisolone or equivalent with a plan to taper 
over 4 to 6  weeks.(84) If there is no improvement in 
3 days, mycophenolate mofetil or azathioprine can be 
offered. Monitoring through laboratory tests should 
be increased to daily or every other day with possible 
inpatient monitoring.
Grade 4 hepatotoxicity (decompensated liver func-
tion, AST OR ALT >20× ULN, and/or total biliru-
bin >10× ULN) should be managed by permanently 
discontinuing checkpoint inhibitor therapy and 
immediately administering 2  mg/kg/day of methyl-
prednisolone equivalent with a plan to taper over 4 
to 6 weeks once symptoms improve to grade 1 or less. 
However, it has to be acknowledged that these rec-
ommendations are not evidence based and hopefully 
await further studies.
If there is no improvement over 3 days, mycopheno-
late mofetil should be started as well. Daily laboratory 
results should be monitored along with the option of 
inpatient monitoring, and infliximab should be avoided 
given the risk of development of liver failure.(84)
Prevention of HBV 
Reactivation
Reactivation of HBV can be defined as a rise in 
HBV DNA compared to baseline and reverse sero-
conversion from hepatitis B surface antigen (HBsAg) 
negative to HBsAg positive for patients who are 
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HBsAg negative and anti-hepatitis B core antigen 
(HBc) positive.(102) In moderate to high-prevalent 
regions of HBV, HBV testing (HBsAg and anti-
HBc) is recommended before initiation of immuno-
suppressive therapy.(102) Three randomized controlled 
trials support starting prophylaxis before initiation 
of immunosuppressive therapy for patients who are 
HBsAg positive and anti-HBc positive, given the high 
risk of reactivation.(102) On the other hand, patients 
who are HBsAg negative but anti-HBc positive can 
be monitored closely for reactivation with ALT, HBV 
DNA, and HBsAg to screen for treatment. The only 
exceptions would be for patients receiving anti-CD20 
antibody therapy or stem cell transplantation for 
which prophylaxis is recommended. When indicated, 
regardless of baseline HBV-DNA level, prophy-
lactic therapy should be started as soon as possible 
or at latest at the time of immunosuppressive ther-
apy. Preferred choice of agent is usually a first-line 
nucleoside/nucleotide analogue due to multiple meta- 
analyses showing reduced reactivation, mortality, 
and therapy interruption.(102) The most commonly 
studied duration for prophylactic therapy is around 
6-12 months, but because reactivation has been 
reported past 12 months, further monitoring should 
be considered for up to 12 months after cessation of 
anti-HBV therapy.
Re-initiation of TNF-α 
Therapy
Certain patients who have developed liver injury 
from one TNF-α inhibitor have been able to tolerate 
re-initiation of TNF-α inhibitor treatment after res-
olution of the initial injury.(28,33,54,61,103) For example, 
2 patients who had been treated with infliximab for 
corticosteroid-dependent IBD developed DILI, but 
after discontinuing infliximab they were successfully 
transitioned to other agents. Both patients were success-
fully started on adalimumab without any signs of cross- 
reactivity, and liver tests remained normal for 6 months 
following initiation.(28,33) Similar cases have also been 
described with patents being treated for rheumatologic 
conditions. One patient being treated for seronegative 
RA with etanercept was switched to adalimumab after 
a year due to loss of efficacy but was soon diagnosed 
with adalimumab-induced AIH.(68) After steroid 
therapy and normalization of liver enzymes after 
6  weeks, she was started on abatacept without fur-
ther elevation of liver enzymes.(68) Two other patients 
with spondyloarthropathy found to have infliximab- 
induced liver injury were also successfully transi-
tioned to etanercept without recurrence of original 
injury.(21,57)
Due to limited data available, there is no consen-
sus on when to rechallenge patients with documented 
episodes of biologic-induced liver injury. Based on 
successful case reports of switching agents without 
recurrence, the common practice has been to stop the 
offending medication and wait to rechallenge until 
the patient was asymptomatic with resolution of lab-
oratory signs of injury. This was achieved both by 
removing the offending agent in some cases and in 
others with treatment with corticosteroids. There are 
no current guidelines or recommendations on mini-
mal time needed before initiation after normalization 
of symptoms and laboratory values.
Conclusions
Biologics remain one of the main treatment alterna-
tives for several chronic inflammatory diseases. TNF-α 
inhibitors have been more frequently documented in 
causing liver injury when assessing its clinical use and 
safety risk compared with other biologics. There may be 
various factors that play a role in developing such toxic 
effects, such as both host and medication characteristics, 
that may confound findings. Prognosis is favorable with 
cessation of the offending drug and corticosteroids, spe-
cifically in patients with autoimmune features. Recent 
case reports have also supported rechallenging patients 
with a different TNF-α inhibitor after resolution of the 
initial liver injury that have not resulted in recurrence of 
the original liver injury.
Although there are cases documenting a success-
ful transitioning and rechallenging from one TNF-α 
inhibitor to another without recurrence of the initial 
observed liver injury, more information is needed to 
further investigate cross-reactivity. This may also 
lead to further discovery regarding the mechanism of 
action of liver injury secondary to TNF-α inhibitors 
given the skewed documentation revealing various 
forms of infliximab-induced liver injury.
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